Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of a Combination of Thrombopoietin Receptor Agonist with an Immunosuppressant Therapy for the Management of Multirefractory Adult ITP: Results from a Retrospective, Multicenter, Observational Study

Etienne Crickx, Guillaume Moulis, Marc Ruivard, Bouchra Asli, Jean Pierre Marolleau, Mikael Ebbo, Etienne Riviere, Sylvain Audia, Louis Terriou, Marc Michel, Bertrand Godeau, Matthieu Mahevas

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-143031

Published: 2020

Journal Articles

Clinical and Biological Features Of Multiple Myeloma (MM) and Monoclonal Gammopathies In Patients With Human Immunodeficiency Virus (HIV) Infection

Alexis Talbot, MD, Laurence Gérard, MD, Raphael Szalat, MD, David Boutboul, Stephanie Harel, MD, Anne Lazareth, Marion Malphettes, MD, PhD, Bouchra Asli, MD, Lionel Galicier, MD, Claire Fieschi, MD, PhD, Eric Oksenhendler, MD, Jean Paul Fermand, MD, Bertrand Arnulf, MD, PhD

Blood (2013) 122 (21): 5348.

https://doi.org/10.1182/blood.V122.21.5348.5348

Published: 2013

Journal Articles

Impact of Tandem Autologous/Non Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma Relapsing After a First High Dose Therapy in the Era of Novels Anti-Myeloma Agents

Stephanie Harel, MD, Sophie Bernard, Sylvie Chevret, Regis Peffault de Latour, Lionel Karlin, MD, Marie Robin, MD, PhD, Lionel Ades, MD, PhD, Raphael Szalat, MD, Marion Malphette, Bouchra Asli, MD, Jean Paul Fermand, MD, Bertrand Arnulf, MD, PhD, Gerard Socie

Blood (2012) 120 (21): 2035.

https://doi.org/10.1182/blood.V120.21.2035.2035

Published: 2012

Journal Articles

Prognostic Value of the Different MMSET Gene Breakpoints and Correlation with Immunoglobulin Isotype and FGFR3 Expression in 173 Patients with t(4;14) Multiple Myeloma

Bertrand Arnulf, MD, PhD, Anne Lazareth, Jean Soulier, MD, PhD, Stephanie Harel, MD, Lionel Karlin, MD, Damien Roosweil, Karim Belhadj, Jerome Tamburini, Arnaud Jaccard, Raphael Szalat, Bouchra Asli, MD, Marion Malphettes, MD, PhD, jean Christophe Bories, Jean Paul Fermand, MD

Blood (2012) 120 (21): 3971.

https://doi.org/10.1182/blood.V120.21.3971.3971

Published: 2012

Journal Articles

Total Body Irradiation (TBI) or Busulfan (Bu) Plus High Dose Melphalan After Bortezomib (Bz) Containing Regimen As Front Line Treatment of High Risk Multiple Myeloma (MM) Patients with 17p Deletion and/or t(4;14) Translocation

Bertrand Arnulf, MD, PhD, Raphael Szalat, MD, Lionel Karlin, MD, Stephanie Harel, MD, Bouchra Asli, MD, Marion Malphettes, MD, PhD, Jean Soulier, MD, Jean Paul Fermand, MD

Blood (2011) 118 (21): 4501.

https://doi.org/10.1182/blood.V118.21.4501.4501

Published: 2011

Journal Articles

Increased Angiogenesis and Enhanced Bone Formation in Patients with IgM Monoclonal Gammopathy and Urticarial Skin Rash: New Insight Into the Biology of the Schnitzler Syndrome

Evangelos Terpos, Bouchra Asli, MD, Dimitrios Christoulas, Jean-Claude Brouet, Efstathios Kastritis, Michel Rybojad, Meletios Athanasios Dimopoulos, MD, Jean Paul Fermand, MD

Blood (2011) 118 (21): 1802.

https://doi.org/10.1182/blood.V118.21.1802.1802

Published: 2011

Journal Articles

Pathogenesis and treatment of xanthomatosis associated with monoclonal gammopathy

Raphael Szalat, Bertrand Arnulf, Lionel Karlin, Michel Rybojad, Bouchra Asli, Marion Malphettes, Lionel Galicier, Marie-Dominique Vignon-Pennamen, Stéphanie Harel, Florence Cordoliani, Jean Gabriel Fuzibet, Eric Oksenhendler, Jean-Pierre Clauvel, Jean-Claude Brouet, Jean-Paul Fermand

Blood (2011) 118 (14): 3777–3784.

https://doi.org/10.1182/blood-2011-05-356907

Published: 2011

Journal Articles

Lenalidomide Therapy in Nine Patients with POEMS Syndrome.

Arnaud Jaccard, Julie Abraham, Christian Recher, Remy Dulery, Isabelle Guichard, Julien Haroche, Bouchra Asli, Zahir Amoura, Jean Marie Brissaud, Lucille Musset, MD, Thierry Facon, Veronique Leblond, Philippe Moreau, Jean-Paul Fermand, Dominique Bordessoule

Blood (2009) 114 (22): 3872.

https://doi.org/10.1182/blood.V114.22.3872.3872

Published: 2009

Journal Articles

Rituximab, Fludarabine and Alkylating Agents in Peripheral Neuropathies Related to IgM Monoclonal Gammopathy with Autoantibody Activity against Myelin-Associated-Glycoprotein : a Retrospective Study of 15 Patients.

Lionel Karlin, Bertrand Arnulf, Lionel Galicier, Bouchra Asli, Marion Malphettes, Claire Fieschi, Sophie Cereja, Eric Oksenhendler, Jean-Paul Fermand, Jean-Claude Brouet

Blood (2009) 114 (22): 3883.

https://doi.org/10.1182/blood.V114.22.3883.3883

Published: 2009

Journal Articles

Combination of Bortezomib and Dexamethasone (VD) or Bortezomib, Adriamycine and Dexamethasone (PAD) Followed by High Dose Therapy and Peripheral Blood Stem Cell Transplantation in First-Line Treatment of T(4;14) Multiple Myeloma : a Prospective Study of the MAG Group.

Lionel Karlin, David Ghez, Marie-Olivia Chandesris, Sylvain Choquet, Margaret Macro, Didier Bouscary, Sophie Cereja, Marion Malphettes, Bouchra Asli, Vincent Levy, Jean Soulier, Jean-Paul Fermand, Bertrand Arnulf

Blood (2009) 114 (22): 3408.

https://doi.org/10.1182/blood.V114.22.3408.3408

Published: 2009

Journal Articles

Use of the Propensity Score Matching Method to Reduce Recruitment Bias in Observational Studies: Application to the Estimation of Survival Benefit of Non-Myeloablative Allogeneic Transplantation In Patients with Multiple Myeloma Relapsing after a First Autologous Transplantation.

Lionel Karlin, Bertrand Arnulf, Sylvie Chevret, Marie Robin, Regis Peffault de Latour, Marion Malphettes, Nabil Kabbara, Bouchra Asli, Lionel Adès, Vanderson Rocha, Jean-Paul Fermand, Gerard Socié

Blood (2008) 112 (11): 1133.

https://doi.org/10.1182/blood.V112.11.1133.1133

Published: 2008

Journal Articles

A Prospective Study of t(4;14) Multiple Myeloma.

Lionel Karlin, MD, David Ghez, MD, Sylvain Choquet, MD, PhD, Karim Belhadj, MD, Margaret Macro, MD, Didier Bouscary, MD, PhD, Jean Soulier, MD, PhD, Raphael Porcher, PhD, Marion Malphettes, MD, Bouchra Asli, MD, Jean-Claude Brouet, MD, PhD, Jean-Paul Fermand, MD, PhD, Bertrand Arnulf, MD, PhD

Blood (2007) 110 (11): 414.

https://doi.org/10.1182/blood.V110.11.414.414

Published: 2007

NARROW

Efficacy and Safety of a Combination of Thrombopoietin Receptor Agonist with an Immunosuppressant Therapy for the Management of Multirefractory Adult ITP: Results from a Retrospective, Multicenter, Observational Study

Clinical and Biological Features Of Multiple Myeloma (MM) and Monoclonal Gammopathies In Patients With Human Immunodeficiency Virus (HIV) Infection

Impact of Tandem Autologous/Non Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma Relapsing After a First High Dose Therapy in the Era of Novels Anti-Myeloma Agents

Prognostic Value of the Different MMSET Gene Breakpoints and Correlation with Immunoglobulin Isotype and FGFR3 Expression in 173 Patients with t(4;14) Multiple Myeloma

Total Body Irradiation (TBI) or Busulfan (Bu) Plus High Dose Melphalan After Bortezomib (Bz) Containing Regimen As Front Line Treatment of High Risk Multiple Myeloma (MM) Patients with 17p Deletion and/or t(4;14) Translocation

Increased Angiogenesis and Enhanced Bone Formation in Patients with IgM Monoclonal Gammopathy and Urticarial Skin Rash: New Insight Into the Biology of the Schnitzler Syndrome

Pathogenesis and treatment of xanthomatosis associated with monoclonal gammopathy

Lenalidomide Therapy in Nine Patients with POEMS Syndrome.

Rituximab, Fludarabine and Alkylating Agents in Peripheral Neuropathies Related to IgM Monoclonal Gammopathy with Autoantibody Activity against Myelin-Associated-Glycoprotein : a Retrospective Study of 15 Patients.

Combination of Bortezomib and Dexamethasone (VD) or Bortezomib, Adriamycine and Dexamethasone (PAD) Followed by High Dose Therapy and Peripheral Blood Stem Cell Transplantation in First-Line Treatment of T(4;14) Multiple Myeloma : a Prospective Study of the MAG Group.

Use of the Propensity Score Matching Method to Reduce Recruitment Bias in Observational Studies: Application to the Estimation of Survival Benefit of Non-Myeloablative Allogeneic Transplantation In Patients with Multiple Myeloma Relapsing after a First Autologous Transplantation.

A Prospective Study of t(4;14) Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only